Perceptive Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Perceptive Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-421	Closed	-$11K	–	198
2016 Q4	$11K	Sell	421 -244,129	-100%	-$5.45M	﹤0.01%	163
2016 Q3	$6.05M	Sell	244,550 -5,450	-2%	-$123K	0.39%	61
2016 Q2	$5.09M	Buy	250,000 +50,000	+25%	+$887K	0.35%	56
2016 Q1	$3.05M	Buy	+200,000	New	+$2.61M	0.27%	75
2015 Q3	–	Sell	-19,470	Closed	-$331K	–	183
2015 Q2	$331K	Buy	+19,470	New	+$277K	0.02%	139
2015 Q1	–	Sell	-22,285	Closed	-$185K	–	173
2014 Q4	$185K	Buy	+22,285	New	+$187K	0.02%	146

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Perceptive Advisors's SUPN Position: Q1 2017 in Review

Perceptive Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q1 2017, closing a stake of 421 shares — an estimated $11K sold.

Perceptive Advisors first reported a position in SUPN in Q4 2014 and held it in 6 quarters. The position peaked at $6.05M in Q3 2016. 246 funds tracked by Wall St. Rank hold SUPN as of Q1 2017.

Perceptive Advisors reported no remaining Supernus Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Perceptive Advisors sold 421 Supernus Pharmaceuticals shares in Q1 2017, an estimated $11K.
Perceptive Advisors first reported a position in Supernus Pharmaceuticals in Q4 2014 and held it in 6 quarters.
Perceptive Advisors's Supernus Pharmaceuticals position peaked at $6.05M in Q3 2016.
246 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2017.

Based on Perceptive Advisors's 13F filing for Q1 2017, filed 15 May 2017.